GLOW
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
GLOW combines BPC-157 (the healing pentadecapeptide), TB-500 (a thymosin-beta-4 fragment), and GHK-Cu (the blue copper peptide) into a single subcutaneous blend. The logic is straightforward and the reason the stack exists: BPC-157 and TB-500 handle deep-tissue repair and recovery, while GHK-Cu handles collagen, connective tissue, and skin. It’s marketed for recovery plus an aesthetic “glow,” and the street taxonomy is real — Bakri confirms “Wolverine” (BPC + TB-500) plus GHK-Cu is exactly the “glow stack” people have converged on.
Each component has its own full wiki page and evidence story. This page covers the rationale for running them together, what each brings, and the honest state of the science.
What does it do in my body?
GLOW bundles three complementary mechanisms:
- BPC-157 drives angiogenesis (new blood-vessel growth) and works through the FAK–paxillin and nitric-oxide pathways to accelerate tissue repair; in one tendon model it increased growth-hormone receptor density on the tendon.
- TB-500 binds actin, the protein skeleton cells use to move, and promotes cell migration into wounds — which is precisely why it’s paired with BPC-157 for repair.
- GHK-Cu carries copper into fibroblasts and signals them to lay down collagen and elastin, regulating both synthesis and breakdown (remodeling).
These slot together cleanly: BPC and TB do the structural repair, GHK-Cu does the skin and connective-tissue rebuild and the gene-expression reset. Dr. Jones makes the sharpest case for why this particular combination is coherent — GHK-Cu lives in two categories at once, longevity and repair, and that dual nature is, in his words, “why the GLOW stack actually works”. The component mechanisms are well-characterized individually; the combination rationale is the natural extension of putting a repair signal, a migration signal, and a collagen/remodeling signal in the same protocol.
How can it help me?
Three of the most-used regenerative peptides in one vial: deep-tissue repair, cell migration, and collagen/copper signaling. GLOW is built on a clear component-evidence rationale — repair peptides plus the skin peptide — and it’s one of the most popular stacks in the space. Here’s what each part does, what the research shows, how people run it, and how to get a verified-clean vial.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No blend-level safety dataset exists, so this is assembled from the components and from user reports — all generally mild:
- Injection-site reactions — redness, swelling, occasional bruising, plus a copper-related sting from the GHK-Cu fraction — are the most common reports. Rotating sites and dosing with food (for GHK-Cu GI upset) are the standard mitigations.
- BPC-157: occasional mild fatigue or digestive change anecdotally; a theoretical VEGF/angiogenesis consideration (more tissue and vessels overlaps machinery a latent tumor could use) — no carcinogenic signal in animal data, but worth knowing.
- GHK-Cu copper load: avoid in Wilson’s disease and hemochromatosis; practitioner guides also flag pregnancy and under-18, and caution with active cancer.
- WADA: BPC-157 and TB-500 are prohibited for competitive athletes — relevant if you compete tested.
No serious adverse events surface in the indexable community reports for the stack, which is reassuring without being a formal safety profile. Cycling and staying in the conventional dose range is how users manage the unknowns.
Regulatory status: Not FDA-approved. None of the three components is approved for human injection; GHK-Cu is approved only as a topical cosmetic ingredient. Injectable GHK-Cu, BPC-157, and KPV were moved to the FDA’s restricted compounding category in 2023, with a review meeting scheduled for July 2026 [web, Scientific American]. BPC’s acetate form was reportedly removed from Category 2 in April 2026 but not yet placed on Category 1. Alyve sells GLOW research-use-only.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for GLOW are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
The doses and schedules below are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The de-facto convention for GLOW, stated plainly:
- Ratio: a roughly 5:1:1 GHK-Cu : TB-500 : BPC-157 blend is the common commercial pattern; one widely-cited clinic protocol lists BPC-157 5 mg / TB-500 10 mg / GHK-Cu 27–50 mg per vial. Alyve’s GLOW vial is a 70 mg total blend (COA shows GHK-Cu 49.64 mg of that).
- Reconstitution: total mg ÷ mL of BAC water = mg/mL; draw your target dose on a U-100 insulin syringe. A common approach is 2–3 mL BAC water in the vial, then a daily 10-unit draw, cycled 4–6 weeks on with time off. Refrigerate the reconstituted solution and use within ~14 days [Alyve handling copy].
- Trade-off vs. buying separately: GLOW fixes the ratio, so you can’t independently titrate each component the way you could with standalone BPC-157, TB-500, and GHK-Cu. That’s the cost of the convenience — and the benefit is one verified vial, one reconstitution, one injection.
Expert disagreement worth knowing. One practitioner is against putting GHK-Cu in the same vial as growth-factor peptides like BPC and TB-500, citing receptor competition and conflicting signals; his rule is GHK-Cu in the morning, other peptides hours later. The counter-position comes from people who compound these for a living: Kirkland says GLOW-type blends look clean on HPLC after years of formulating, and the real failure mode is a couple of specific incompatible pairs (retatrutide + NAD), not blends in general. Dr. Jones endorses GLOW directly. So: one practitioner’s single-vial objection is a real argument, but it’s contestable, and the stability of the actual product is confirmed by HPLC. Show both sides; the evidence and Rick decide.
Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.
What should I avoid combining — and what's synergistic?
GLOW doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
- SKU: GLOW (BPC-157 / TB-500 / GHK-Cu), 70 mg blend — $118.00 on sale (regular $124). In stock. (
ALYVE-GLOW-BLEND) - Purity: third-party COA from Freedom Diagnostics Testing — 99.16% purity, identity-confirmed (GHK-Cu/TB-500/BPC-157) by LC-MS, lot GLO951.
- Why that matters: a blend is only as trustworthy as its components, and a three-peptide vial is exactly where gray-market quality problems compound — wrong peptide, off-ratio, TFA-salt contamination. This isn’t hypothetical: a 2026 Mendias-group preprint that purity-tested 6,441 gray-market peptide samples across 14 compounds (including BPC-157, GHK-Cu, and TB-500 — every GLOW component) is exactly the kind of market-wide data that quantifies the off-spec problem a COA solves [purity-testing preprint, Mendias group 2026]. Kirkland’s point that GLOW blends hold up on HPLC is reassuring in principle; a per-batch COA proves it for the specific vial in your hand. Alyve’s >99% identity-confirmed result is the verified-clean tier this category badly needs.
- Offer: use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. A 4–6 week cycle plus the recovery use-case makes the 3-bottle stack the natural commitment buy.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
Three of the most-used regenerative peptides in one vial: deep-tissue repair, cell migration, and collagen/copper signaling. GLOW is built on a clear component-evidence rationale — repair peptides plus the skin peptide — and it’s one of the most popular stacks in the space. Here’s what each part does, what the research shows, how people run it, and how to get a verified-clean vial.
What it is
GLOW combines BPC-157 (the healing pentadecapeptide), TB-500 (a thymosin-beta-4 fragment), and GHK-Cu (the blue copper peptide) into a single subcutaneous blend. The logic is straightforward and the reason the stack exists: BPC-157 and TB-500 handle deep-tissue repair and recovery, while GHK-Cu handles collagen, connective tissue, and skin. It’s marketed for recovery plus an aesthetic “glow,” and the street taxonomy is real — Bakri confirms “Wolverine” (BPC + TB-500) plus GHK-Cu is exactly the “glow stack” people have converged on.
Each component has its own full wiki page and evidence story. This page covers the rationale for running them together, what each brings, and the honest state of the science.
How it works
GLOW bundles three complementary mechanisms:
- BPC-157 drives angiogenesis (new blood-vessel growth) and works through the FAK–paxillin and nitric-oxide pathways to accelerate tissue repair; in one tendon model it increased growth-hormone receptor density on the tendon.
- TB-500 binds actin, the protein skeleton cells use to move, and promotes cell migration into wounds — which is precisely why it’s paired with BPC-157 for repair.
- GHK-Cu carries copper into fibroblasts and signals them to lay down collagen and elastin, regulating both synthesis and breakdown (remodeling).
These slot together cleanly: BPC and TB do the structural repair, GHK-Cu does the skin and connective-tissue rebuild and the gene-expression reset. Dr. Jones makes the sharpest case for why this particular combination is coherent — GHK-Cu lives in two categories at once, longevity and repair, and that dual nature is, in his words, “why the GLOW stack actually works”. The component mechanisms are well-characterized individually; the combination rationale is the natural extension of putting a repair signal, a migration signal, and a collagen/remodeling signal in the same protocol.
What the research shows
Honest framing up front: there is no published study of the three-peptide combination itself — a PubMed search for BPC-157 + TB-500 + GHK-Cu returns zero records in any model [PubMed: 0 records]. That combination gap is real and is tracked in questions.md. What GLOW is built on is the component evidence, which is what every practitioner running it is actually relying on. By tier:
GHK-Cu — the best-evidenced component:
- Topical human cosmetic studies (40–71 women, 12 weeks) showing firmer, denser skin, reduced fine lines, improved elasticity; a comparative trial showed collagen deposition in 70% of users vs. 50% for vitamin C.
- Injectable form: consistent animal collagen/wound data (rats, dogs).
- The “28% collagen” figure is a McGill press release, not yet a peer-reviewed paper — treat as a reported finding.
- Strong, consistent animal data for tendon, ligament, muscle, nerve, and gut healing; striking CNS-regeneration findings.
- Human data is thin: a 2024 systematic review of 544 screened articles found one clinical study (a 12-patient retrospective case series), plus older small Phase 1/2 ulcerative-colitis enema trials with no reported toxicity. No carcinogenic signal in animal data; in a melanoma model BPC actually decreased VEGF.
- Animal and in-vitro repair data. Human trials exist for pharmaceutical-grade thymosin beta-4 (full 43-aa protein and clinical eye drops) — promising in dry eye/neurotrophic keratopathy — but those used the clinical protein, not the 7-aa research fragment. A 2025 STEMI RCT of recombinant Tβ4 found no significant overall infarct-size reduction.
One place that reviews all three together: the 2026 Mendias musculoskeletal-peptide review covers BPC-157, TB-500, and GHK-Cu (alongside AOD-9604, CJC-1295, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin) in a single safety-and-efficacy survey — a useful, current, one-stop reference for the components that make up GLOW [REVIEW preprint, Mendias 2026, DOI 10.20944/preprints202512.1011.v3]. It’s a preprint, so it’s a map of the component evidence, not new combination data — but it’s the closest thing to a single document that treats the whole stack’s ingredients at once.
On the repair base (BPC + TB-500), the real-world signal is strong even though the trial signal is thin. The BPC-157 + TB-500 pairing inside GLOW is the same “Wolverine” base that peptide clinics run as their default healing protocol, and the user-experience tier supplies the vivid anecdotes — e.g. a near-complete jiu-jitsu tricep tear back to training in ~3 months and a 2-decade chronic elbow tendonitis “almost completely gone” in 8 weeks. Tag these as n=1 experience, not efficacy data — but they’re the kind of repeated real-world result that explains why the base stack is so widely used. GHK-Cu adds the documented age-decline restoration angle (serum GHK-Cu falls ~60% from age 20 to 60), which is the mechanistic logic behind the “glow.”
Where it stands: the strongest single piece (topical GHK-Cu) has real human backing; the repair components are predominantly animal-grade for the injectable route, which is normal for bleeding-edge peptides. Clinic copy sometimes attaches quantified numbers to the blend — “200% faster healing,” “70% collagen improvement,” “fine lines in 2–3 weeks” — those are extrapolated or unsourced, not measured for the combination, so we don’t repeat them as combination facts. The defensible claim is the one the components support: a coherent repair-plus-skin stack whose individual signals are real, whose combination is plausible and widely used, and whose formal combination study is the field’s open gap.
Real-world protocol
The doses and schedules below are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The de-facto convention for GLOW, stated plainly:
- Ratio: a roughly 5:1:1 GHK-Cu : TB-500 : BPC-157 blend is the common commercial pattern; one widely-cited clinic protocol lists BPC-157 5 mg / TB-500 10 mg / GHK-Cu 27–50 mg per vial. Alyve’s GLOW vial is a 70 mg total blend (COA shows GHK-Cu 49.64 mg of that).
- Reconstitution: total mg ÷ mL of BAC water = mg/mL; draw your target dose on a U-100 insulin syringe. A common approach is 2–3 mL BAC water in the vial, then a daily 10-unit draw, cycled 4–6 weeks on with time off. Refrigerate the reconstituted solution and use within ~14 days [Alyve handling copy].
- Trade-off vs. buying separately: GLOW fixes the ratio, so you can’t independently titrate each component the way you could with standalone BPC-157, TB-500, and GHK-Cu. That’s the cost of the convenience — and the benefit is one verified vial, one reconstitution, one injection.
Expert disagreement worth knowing. One practitioner is against putting GHK-Cu in the same vial as growth-factor peptides like BPC and TB-500, citing receptor competition and conflicting signals; his rule is GHK-Cu in the morning, other peptides hours later. The counter-position comes from people who compound these for a living: Kirkland says GLOW-type blends look clean on HPLC after years of formulating, and the real failure mode is a couple of specific incompatible pairs (retatrutide + NAD), not blends in general. Dr. Jones endorses GLOW directly. So: one practitioner’s single-vial objection is a real argument, but it’s contestable, and the stability of the actual product is confirmed by HPLC. Show both sides; the evidence and Rick decide.
Side effects & management
No blend-level safety dataset exists, so this is assembled from the components and from user reports — all generally mild:
- Injection-site reactions — redness, swelling, occasional bruising, plus a copper-related sting from the GHK-Cu fraction — are the most common reports. Rotating sites and dosing with food (for GHK-Cu GI upset) are the standard mitigations.
- BPC-157: occasional mild fatigue or digestive change anecdotally; a theoretical VEGF/angiogenesis consideration (more tissue and vessels overlaps machinery a latent tumor could use) — no carcinogenic signal in animal data, but worth knowing.
- GHK-Cu copper load: avoid in Wilson’s disease and hemochromatosis; practitioner guides also flag pregnancy and under-18, and caution with active cancer.
- WADA: BPC-157 and TB-500 are prohibited for competitive athletes — relevant if you compete tested.
No serious adverse events surface in the indexable community reports for the stack, which is reassuring without being a formal safety profile. Cycling and staying in the conventional dose range is how users manage the unknowns.
Regulatory status
Not FDA-approved. None of the three components is approved for human injection; GHK-Cu is approved only as a topical cosmetic ingredient. Injectable GHK-Cu, BPC-157, and KPV were moved to the FDA’s restricted compounding category in 2023, with a review meeting scheduled for July 2026 [web, Scientific American]. BPC’s acetate form was reportedly removed from Category 2 in April 2026 but not yet placed on Category 1. Alyve sells GLOW research-use-only.
The Alyve product
- SKU: GLOW (BPC-157 / TB-500 / GHK-Cu), 70 mg blend — $118.00 on sale (regular $124). In stock. (
ALYVE-GLOW-BLEND) - Purity: third-party COA from Freedom Diagnostics Testing — 99.16% purity, identity-confirmed (GHK-Cu/TB-500/BPC-157) by LC-MS, lot GLO951.
- Why that matters: a blend is only as trustworthy as its components, and a three-peptide vial is exactly where gray-market quality problems compound — wrong peptide, off-ratio, TFA-salt contamination. This isn’t hypothetical: a 2026 Mendias-group preprint that purity-tested 6,441 gray-market peptide samples across 14 compounds (including BPC-157, GHK-Cu, and TB-500 — every GLOW component) is exactly the kind of market-wide data that quantifies the off-spec problem a COA solves [purity-testing preprint, Mendias group 2026]. Kirkland’s point that GLOW blends hold up on HPLC is reassuring in principle; a per-batch COA proves it for the specific vial in your hand. Alyve’s >99% identity-confirmed result is the verified-clean tier this category badly needs.
- Offer: use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. A 4–6 week cycle plus the recovery use-case makes the 3-bottle stack the natural commitment buy.
Sources
- PubMed: combination search = 0 records (0019 corpus: 4 review-only co-mentions, no primary combination study — the honest framing this page uses). Components — PMIDs 26236730, 18644225, 8227353, 8669775 (GHK-Cu); 40756949 (BPC-157 systematic review); 41229390 (Tβ4 STEMI RCT); 30063853 (Tβ4 eye-drop human data).
- Preprints (0019): Mendias 2026 musculoskeletal-peptide safety/efficacy review covering BPC-157/TB-500/GHK-Cu + 7 others, DOI 10.20944/preprints202512.1011.v3; Mendias-group 2026 gray-market peptide purity study (6,441 samples / 14 compounds incl. all three GLOW components).
- Web: Revolution Health GLOW blog; Jay Campbell / BioLongevity GLOW protocol; AH-Clinics; Nulevel Wellness; Scientific American “The Science Behind the Peptide Craze” (Apr 2026).
- Video: (Wolverine/glow taxonomy); (GLOW endorsement, dual-category GHK-Cu); (anti-blend argument); (HPLC stability rebuttal); (BPC+TB base case studies); (clinic-default combo); (GHK-Cu age-decline + 4-mechanism map).
- Raw:,.
Components: BPC-157 · TB-500 · GHK-Cu. Related blends: KLOW (GLOW + KPV).